Recombinant Rhesus Macaque Alpha-Galactosidase A Protein，His

Alpha-Galactosidase A (α-Gal A) is an enzyme crucial for the degradation of glycosphingolipids, particularly those containing galactose residues, and is linked to the rare genetic disorder Fabry disease. Patients with Fabry disease experience severe symptoms due to the accumulation of these lipid substrates, leading to vascular, renal, and cardiac complications. The research on recombinant α-Gal A has surged in recent years as a therapeutic approach to replace the deficient enzyme in affected individuals. Advancements in biotechnological methods have enabled the production of recombinant α-Gal A in various expression systems, such as yeast, bacteria, and mammalian cells, enhancing its efficacy and stability. Studies are focused on optimizing these production methods and improving the enzyme's pharmacokinetics and bioavailability. Additionally, understanding the enzyme's structure and function through techniques like X-ray crystallography and mutational analysis has aided in the development of enzyme replacement therapies. As a result, recombinant α-Gal A has proven effective in clinical trials, leading to its approval as a treatment option. Ongoing research aims to refine these therapies further and explore potential gene therapies to address the underlying genetic defect, ultimately improving the quality of life for Fabry disease patients.